Answering the call to address the COVID-19 pandemic
Behind every laboratorian is the support of 53,000 Healthineers

The urgency and complexity of the current COVID-19 situation continues to grow, and laboratorians play an essential role. Testing for SARS-CoV-2 is not the only need in managing COVID-19 patients. Fast, accurate screening and monitoring for the variety of health issues that may arise as part of COVID-19 disease management are also needed.

The essential role of laboratory diagnostics in SARS-CoV-2 infection

We are committed to helping laboratorians navigate this new world, in order to help you provide the best care to patients in this challenging time. A new COVID-19 Laboratory Testing Guide provides timely, relevant content to support the extended role of laboratory diagnostics in managing COVID-19 patients:

  • Transmission and clinical classification
  • Course of patients at risk
  • Current recommendations for laboratory testing
  • Frequent laboratory abnormalities
  • Impact of patients with co-morbidities

At Siemens Healthineers, we are fully committed to supporting our partners throughout the healthcare system by helping them deliver high-value care to patients.

Total Assay Infographic lab version

SARS-CoV-2 Total Assay1

Secure your community with science and scale
Download the infographic
Total Assay Infographic media version

Not all antibody tests are created equal

High quality, extensive reach and targeting the right protein are all essential to ensure we effectively manage the threat of COVID-19
Download the infographic
COVID-19 infographic

Clinical information for laboratorians

Learn about diagnosis and treatment of COVID-19 patients
Download the infographic
Lab testing and frequent laboratory abnormalities in patients with COVID-19 infographic

The essential role of laboratory diagnostics

Lab testing and frequent laboratory abnormalities in patients with COVID-19
Download the infographic

Diagnostic testing for COVID-19

As a truly emergent human pathogen, a specific test for presence of the virus did not exist with the onset of cases, necessitating rapid development. Most current testing for infection relies on detection of the viral RNA using a reverse-transcription polymerase chain reaction (rtPCR). In addition, serology testing from a blood sample can identify antibody to the virus.1,2 These tests will likely prove extremely valuable for surveillance and could potentially provide assessment for immunity, as well as aiding identification of acute infection.

As availability and supplies for molecular testing for COVID-19 increase, testing turn-around times should improve, but remain contingent on sample collection, proper preanalytical handling (RNA is highly degradable), time to test result, and access to testing (point-of-care vs. lab-based).


AACC Webinar: Cytokine Storm Syndrome and COVID-19

In this webinar, Dr. Randy Cron will discuss criteria for identifying Cytokine storm syndrome (CSS) in patients, complications, and available treatments which include glucocorticoids, but also targeted therapies that dampen pro-inflammatory cytokines like interleukin-1 (IL-1) and IL-6.

Speaker:
Randy Q. Cron, MD, PhD
University of Alabama at Birmingham


AACC Webinar: The Role of Laboratory Diagnostics in SARS-CoV-2 Infection and Related Comorbidities

Experiences and Population Management Strategies from Highly Affected Regions of China and Italy: Laboratory tests are vital throughout many clinical pathways, and this webinar describes how laboratory medicine can efficiently help combat the COVID-19 outbreak.

Speakers:
Prof. Mario Plebani
Professor of Clinical Biochemistry and Clinical Molecular Biology, University of Padova School of Medicine
Chief, Department of Laboratory Medicine, University Hospital, Padova, Italy

Prof. Shu Kui Wang
Vice Dean
Director of Central Laboratory
Nanjing First Hospital, Nanjing Medical University, Nanjing, China

Watch the webinar today

COVID-19 Laboratory Testing Guide

Testing is critical to differentiate COVID-19 from other respiratory disease such as influenza or RSV (respiratory syncytial virus). Widespread testing will both inform a COVID-19 diagnosis and aid a greater understanding of disease prevalence, especially in infections that are asymptomatic.

Download the COVID-19 Laboratory Testing Guide

COVID-19 Booklet

  • What are the symptoms of COVID-19?
  • How does COVID-19 progress?
  • How to test for, treat, and immunize
  • How are COVID-19 tests administered?
  • How to avoid spreading COVID-19
Download the COVID-19 Booklet

Download eBook: Coagulation abnormalities in COVID-19 patients

As part of our commitment to labs and clinicians in the fight against the pandemic, we aim to keep you informed on current coagulation testing and monitoring recommendations in COVID-19 patients. Read our eBook for an overview on:

  • Thrombosis risk factors
  • ISTH-recommended coagulation testing algorithm
  • Leading recommendations for anticoagulation treatment
  • Relevant parameters for patient monitoring
Download the eBook

Partagez cette page:

The products/features (mentioned herein) are not commercially available in all countries. Due to regulatory reasons their future availability cannot be guaranteed. Please contact your local Siemens Healthineers organization for further details.

1. Ehterinton, D. https://techcrunch.com/2020/03/27/the-fda-just-okayed-multiple-15-minute-blood-tests-to-screen-for-coronavirus-but-there-are-caveats/ (Accessed March 28, 2020)

2. Morris, A. https://www.azcentral.com/story/news/local/arizona-health/2020/03/28/university-arizona-working-tests-detect-covid-19-antibodies/5083093002/ (Accessed March 28, 2020)

*Under development. Not available for sale. Future availability cannot be guaranteed.

**CE-IVD labelled for diagnostic use in the EU. For research use only (RUO) in the U.S. Pursuing FDA emergency use authorization (EUA) and WHO emergency use listing (EUL).

***This test has not been FDA cleared or approved. This test has been authorized by FDA under an EUA for use by authorized laboratories. This test has been authorized only for detecting the presence of antibodies against SARS-CoV-2, not for any other viruses or pathogens. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Product availability may vary by country and is subject to regulatory requirements.